{"schema_version":"secwatch.filing_event.v1","accession":"0001062822-25-000003","form_type":"8-K","ticker":"LXRX","cik":"0001062822","company_name":"LEXICON PHARMACEUTICALS, INC.","filed_at":"2025-01-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.842269+00:00","generated_at":"2026-05-28T17:28:11.016814+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Lexicon appoints Scott M. Coiante as CFO; base salary $450K, option for 230K shares","bullets":["Scott M. Coiante named SVP and CFO effective Jan 2, 2025; Kristen Alexander remains principal accounting officer.","Base salary $450K; annual cash bonus target 40% of base salary.","Granted option to purchase 230K shares vesting 25% after 1 year then 1/48th monthly.","Coiante previously CFO at Agile Therapeutics and Aprea Therapeutics."],"urls":{"canonical":"https://secwatch.observer/filing/0001062822-25-000003","json":"https://secwatch.observer/filing/0001062822-25-000003.json","markdown":"https://secwatch.observer/filing/0001062822-25-000003.md","text":"https://secwatch.observer/filing/0001062822-25-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1062822/000106282225000003/0001062822-25-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1062822/000106282225000003/lxrx-20250102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T17:28:11.016814+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"146ee75126","claim":"Scott M. Coiante was appointed as senior vice president and chief financial officer at LEXICON PHARMACEUTICALS, INC..","evidence_excerpt":"Effective as of January 2, 2025, Scott M. Coiante was appointed as our senior vice president and chief financial officer, in which capacity he will function as our principal financial officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282225000003/0001062822-25-000003-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"senior vice president and chief financial officer"}],"fact_type":"executive_change"},{"claim_id":"dcfcb5b2f3","claim":"Kristen L. Alexander changed role as vice president, finance and accounting at LEXICON PHARMACEUTICALS, INC..","evidence_excerpt":"Kristen L. Alexander, our vice president, finance and accounting, relinquished her function as our principal financial officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282225000003/0001062822-25-000003-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"relinquished"},{"label":"Role","value":"vice president, finance and accounting"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}